Distributor eNewsletter | March 2014; vol 9

Applications For Development of Biologics

R&D Groups – Cellular Binding, Functional Screening and Potency Determination

Manufacturing or Bioanalytical Groups – Bioassays for QC Lot‐release and Stability Testing

Clinical Immunology Groups –Cell‐based Assays for Detection of Neutralizing Anti‐Drug Antibodies

Download the customer‐facing brochure HERE

Available Target List for Biologics GPCR Assays ADCYAP1R ADORA1 ADORA2A ADORA2B ADORA3 ADRA1A ADRA1B ADRA2A ADRA2B ADRA2C 1 ADRB1 ADRB2 ADRB3 AGTR1 AGTRL1 AVPR1A AVPR1B AVPR2 BAI1 BAI2 CALCR + CALCR + BAI3 BDKRB1 BDKRB2 BRS3 C3AR1 C5AR1 C5L2 CALCR RAMP1 RAMP2 CALCR + CALCRL + CALCRL + CALCRL + CASR CCKAR CCKBR CCR1 CCR10 CCR2 RAMP3 RAMP1 RAMP2 RAMP3 CCR3 CCR4 CCR5 CCR6 CCR7 CCR8 CCRL1 cGPR91 CHRM1 CHRM2 CHRM3 CHRM4 CHRM5 CMKLR1 CNR1 CNR2 CRHR1 CRHR2 CRTH2 CXCR1 CXCR2 CXCR3 CXCR4 CXCR5 CXCR6 CXCR7 CYSLTR2 DARC DRD1 DRD2L DRD2S DRD3 DRD4 DRD5 EBI2 EDG1 EDG2 EDG3 EDG4 EDG5 EDG6 EDG7 EDG8 EDNRA EDNRB F2R F2RL1 F2RL3 FFAR1 FFAR2 FFAR3 FPR1 FPR3 FPRL1 FSHR GALR1 GALR2 GCGR GHRHR GHSR GHSR1b GIPR GLP1R GLP2R GNRHR GPBAR1 GPR1 GPR101 GPR103 GPR107 GPR109A GPR109B GPR119 GPR12 GPR120 GPR120S GPR123 GPR132 GPR135 GPR137 GPR139 GPR141 GPR142 GPR143 GPR146 GPR148 GPR149 GPR15 GPR150 GPR151 GPR152 GPR157 GPR161 GPR162 GPR17 GPR171 GPR173 GPR176 GPR18 GPR182 GPR20 GPR23 GPR25 GPR26 GPR27 GPR3 GPR30 GPR31 GPR32 GPR35 GPR37 GPR37L1 GPR39 GPR4 GPR45 GPR50 GPR52 GPR55 GPR6 GPR61 GPR65 GPR75 GPR78 GPR79 GPR81 GPR83 GPR84 GPR85 GPR88 GPR91 GPR92 GPR97 GRM1 GRM2 GRM3 GRM4 GRM5 GRM6 GRM7 GRPR HCRTR1 HCRTR2 HRH1 HRH2 HRH3 HRH4 HTR1A HTR1B HTR1E HTR1F HTR2A HTR2B HTR2C HTR2C(VGV) HTR2C(VNV) HTR2C(VSV) HTR5A HTR6 HTR7A HTR7B mADORA2 HTR7D KISS1R LGR4 LGR5 LGR6 LHCGR LTB4R mADCYAP1R1 mADORA3 B mADRA1B mAGTRL1 mAVPR2 mBRS3 MC1R MC3R MC4R mC5AR1 MC5R mCCKAR mCCR1 mCCR2 mCCR3 mCCR4 mCCR5 mCCR6 mCCR7 mCCR8 mCCR9 MCHR1 MCHR2 mCMKLR1 mCNR1 mCNR2 mCRHR1 mCRTH2 mCX3CR1 mCXCR2 mCXCR3 mCXCR4 mCXCR5 mCXCR6 mCXCR7 mDRD5 mEDG1 mEDG5 mEDG6 mEDNRA mEDNRB mF2RL1 mFPR1 mGALR1 mGALR2 mGCGR mGHSR mGIPR mGLP1R mGPR1 mGPR120 mHCRTR1 mHTR2A mHTR2C mKISS1R MLNR mLTB4R mMC3R mMC4R mMC5R mMCHR1 mNPY1R mNPY2R mOPRD1 mOPRK1 mOPRM1 mOXTR mP2RY12 mP2RY6 mPPYR1 mPTAFR mPTGIR MRGPRD MRGPRE MRGPRF MRGPRX1 MRGPRX2 MRGPRX4 mRXFP3 mRXFP4 mSSTR2 mSSTR5 mTACR1 MTNR1A MTNR1B mUTR2 mVIPR1 NMBR NMU1R NPBWR1 NPBWR2 NPFFR1 NPSR1b NPY1R NPY2R NTSR1 OPN5 OPRD1 OPRK1 OPRL1 OPRM1 OXER1 OXGR1 OXTR P2RY1 P2RY11 P2RY12 P2RY2 P2RY4 P2RY6 P2RY8 PPYR1

Page 3 Distributor eNewsletter | March 2014; vol 9

GPCR Assays (continued) PRLHR PROKR1 PROKR2 PTAFR PTGDR PTGER1 PTGER2 PTGER3 PTGER4 PTGFR PTGIR PTHR1 PTHR2 rCHRM4 rCNR2 rCRTH2 rDRD1 rDRD2L rDRD2S rEDG5 rGPR35 rHTR2C rOPRM1 rPROKR1 rPROKR2 rPTGER4 rVIPR1 RXFP1 RXFP2 RXFP3 RXFP4 SCTR sEDG5 SSTR1 SSTR2 SSTR3 SSTR4 SSTR5 TAAR1 TAAR5 TACR1 TACR2 TACR3 TBXA2R TRHR TSHR(L) UTR2 VIPR1 VIPR2 XCR1

Kinase Assays

AXL BLK c‐KIT c‐MET c‐Ret‐GFRα2 CSF3R‐JAK1 DDR1 EphA4 EphA5 EphA7 EphB1 EphB2 EphB3 EphB4 EpoR‐JAK2 ErbB1 ErbB2‐ErbB3 ErbB4 FGFR1 FGFR2 FGR FLT3 FLT4 GHR‐JAK1 GHR‐JAK2 IGF1R INSR INSR JAK3 KDR PDGFRa PDGFRb PRLR‐JAK1 PRLR‐JAK2 SYK TrkA TrkA‐P75 TrkB TrkB‐P75 TrkC TrkC‐P75 TYK2 YES1

Signaling Pathway Assays ACVR1 ACVR1/ACVR2 BAX BCL2‐BIM BCL2L1‐BAX BIM FOXO3 GSK3β IL17RC IκB Keap1 Keap1‐NRF2 NFκB NPR1 P53 SREBP2 TGFBR1 TGFBR1/TGFBR2 TGFBR2 TORC1 TORC2 Wnt3 XBP1 β‐Catenin

LeadHunter Services Panel Testing Dates

Test Dates Compounds and PO Due Report and Invoicing

4/1/2014 3/28/2014 4/29/2014 gpcrMAX, 5/13/2014 5/9/2014 6/10/2014 orhpanMAX, 6/24/2014 6/20/2014 7/22/2014 Chemokine and gpcrPANELS 8/5/2014 8/1/2014 9/2/2014 (therapeutic) 9/16/2014 9/12/2014 10/14/2014 10/28/2014 10/24/2014 11/25/2014

3/18/2014 3/14/2014 4/15/2014 4/29/2014 4/25/2014 5/27/2014 6/10/2014 6/6/2014 7/8/2014 nhrMAX and tkMAX 7/22/2014 7/18/2014 8/19/2014 9/2/2014 8/29/2014 9/30/2014 10/14/2014 10/10/2014 11/11/2014 11/25/2014 11/21/2014 12/23/2014

Compound Requirements For specific service or panel specific compound requirements, please visit our Compound Submission page. Generally, compounds may be provided as a stock DMSO solution or dry powder. For single concentration (primary) screens, we need 20 µL of 1000x the desired screening concentration for the first target and an additional 2 µL for each target thereafter or an equivalent amount of dry powder such that when reconstituted, will yield the required volume. For orphan GPCR panels, we require 175 µL of 1000X solution.

Page 4